• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 11-K filed by Neogen Corporation

    6/25/26 5:01:47 PM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $NEOG alert in real time by email
    11-K
    falsefalse0000711377FY0000711377http://www.neogen.com/20251231#FidelityUSBondIndexFundMemberhttp://fasb.org/us-gaap/2025#MutualFundMemberhttp://fasb.org/us-gaap-ebp/2025#EmployeeBenefitPlanParticipantDirectedMemberhttp://www.neogen.com/20251231#FidelityFiveHundredIndexFundMemberhttp://fasb.org/us-gaap/2025#MutualFundMemberhttp://fasb.org/us-gaap-ebp/2025#EmployeeBenefitPlanParticipantDirectedMemberhttp://www.neogen.com/20251231#FidelityMidCapIndexFundMemberhttp://fasb.org/us-gaap/2025#MutualFundMemberhttp://fasb.org/us-gaap-ebp/2025#EmployeeBenefitPlanParticipantDirectedMemberhttp://www.neogen.com/20251231#FidelitySmallCapIndexFundMemberhttp://fasb.org/us-gaap/2025#MutualFundMemberhttp://fasb.org/us-gaap-ebp/2025#EmployeeBenefitPlanParticipantDirectedMemberhttp://www.neogen.com/20251231#FidelityInternationalIndexFundMemberhttp://fasb.org/us-gaap/2025#MutualFundMemberhttp://fasb.org/us-gaap-ebp/2025#EmployeeBenefitPlanParticipantDirectedMemberhttp://fasb.org/us-gaap/2025#MutualFundMemberhttp://www.neogen.com/20251231#FidelityLargeCapGrowthIndexFundMemberhttp://fasb.org/us-gaap-ebp/2025#EmployeeBenefitPlanParticipantDirectedMemberhttp://www.neogen.com/20251231#FidelityLargeCapValueIndexFundMemberhttp://fasb.org/us-gaap/2025#MutualFundMemberhttp://fasb.org/us-gaap-ebp/2025#EmployeeBenefitPlanParticipantDirectedMemberhttp://www.neogen.com/20251231#FidelityGovernmentMoneyMarketFundMemberhttp://fasb.org/us-gaap/2025#MutualFundMemberhttp://fasb.org/us-gaap-ebp/2025#EmployeeBenefitPlanParticipantDirectedMemberhttp://www.neogen.com/20251231#VanguardTargetRetirement2055FundMemberhttp://fasb.org/us-gaap/2025#MutualFundMemberhttp://fasb.org/us-gaap-ebp/2025#EmployeeBenefitPlanParticipantDirectedMemberhttp://www.neogen.com/20251231#VanguardTargetRetirement2065FundMemberhttp://fasb.org/us-gaap/2025#MutualFundMemberhttp://fasb.org/us-gaap-ebp/2025#EmployeeBenefitPlanParticipantDirectedMemberhttp://www.neogen.com/20251231#JPMorganMidCapValueFundClassR6Memberhttp://fasb.org/us-gaap/2025#MutualFundMemberhttp://fasb.org/us-gaap-ebp/2025#EmployeeBenefitPlanParticipantDirectedMemberhttp://www.neogen.com/20251231#VanguardTargetRetirement2020FundMemberhttp://fasb.org/us-gaap/2025#MutualFundMemberhttp://fasb.org/us-gaap-ebp/2025#EmployeeBenefitPlanParticipantDirectedMemberhttp://www.neogen.com/20251231#VanguardTargetRetirement2030FundMemberhttp://fasb.org/us-gaap/2025#MutualFundMemberhttp://fasb.org/us-gaap-ebp/2025#EmployeeBenefitPlanParticipantDirectedMemberhttp://www.neogen.com/20251231#VanguardTargetRetirement2040FundMemberhttp://fasb.org/us-gaap/2025#MutualFundMemberhttp://fasb.org/us-gaap-ebp/2025#EmployeeBenefitPlanParticipantDirectedMemberhttp://www.neogen.com/20251231#VanguardTargetRetirement2050FundMemberhttp://fasb.org/us-gaap/2025#MutualFundMemberhttp://fasb.org/us-gaap-ebp/2025#EmployeeBenefitPlanParticipantDirectedMemberhttp://www.neogen.com/20251231#BairdCorePlusBondFundClassInstitutionalMemberhttp://fasb.org/us-gaap/2025#MutualFundMemberhttp://fasb.org/us-gaap-ebp/2025#EmployeeBenefitPlanParticipantDirectedMemberhttp://www.neogen.com/20251231#VanguardTargetRetirement2070FundMemberhttp://fasb.org/us-gaap/2025#MutualFundMemberhttp://fasb.org/us-gaap-ebp/2025#EmployeeBenefitPlanParticipantDirectedMemberhttp://www.neogen.com/20251231#VanguardEquityIncomeFundAdmiralSharesMemberhttp://fasb.org/us-gaap/2025#MutualFundMemberhttp://fasb.org/us-gaap-ebp/2025#EmployeeBenefitPlanParticipantDirectedMemberhttp://www.neogen.com/20251231#VanguardExplorerFundAdmiralSharesMemberhttp://fasb.org/us-gaap/2025#MutualFundMemberhttp://fasb.org/us-gaap-ebp/2025#EmployeeBenefitPlanParticipantDirectedMemberhttp://www.neogen.com/20251231#VanguardTargetRetirementIncomeFundInvestorSharesMemberhttp://fasb.org/us-gaap/2025#MutualFundMemberhttp://fasb.org/us-gaap-ebp/2025#EmployeeBenefitPlanParticipantDirectedMemberhttp://www.neogen.com/20251231#VanguardTargetRetirement2025FundMemberhttp://fasb.org/us-gaap/2025#MutualFundMemberhttp://fasb.org/us-gaap-ebp/2025#EmployeeBenefitPlanParticipantDirectedMemberhttp://www.neogen.com/20251231#VanguardTargetRetirement2035FundMemberhttp://fasb.org/us-gaap/2025#MutualFundMemberhttp://fasb.org/us-gaap-ebp/2025#EmployeeBenefitPlanParticipantDirectedMemberhttp://www.neogen.com/20251231#VanguardTargetRetirement2045FundMemberhttp://fasb.org/us-gaap/2025#MutualFundMemberhttp://fasb.org/us-gaap-ebp/2025#EmployeeBenefitPlanParticipantDirectedMemberhttp://www.neogen.com/20251231#VanguardInflationProtectedSecuritiesFundAdmiralSharesMemberhttp://fasb.org/us-gaap/2025#MutualFundMemberhttp://fasb.org/us-gaap-ebp/2025#EmployeeBenefitPlanParticipantDirectedMemberhttp://www.neogen.com/20251231#VictoryPioneerStrategicIncomeFundClassR6Memberhttp://fasb.org/us-gaap/2025#MutualFundMemberhttp://fasb.org/us-gaap-ebp/2025#EmployeeBenefitPlanParticipantDirectedMemberhttp://www.neogen.com/20251231#AmericanFundsEuroPacificGrowthFundClassR6Memberhttp://fasb.org/us-gaap/2025#MutualFundMemberhttp://fasb.org/us-gaap-ebp/2025#EmployeeBenefitPlanParticipantDirectedMemberhttp://www.neogen.com/20251231#AmericanFundsAmericanBalancedFundClassR6Memberhttp://fasb.org/us-gaap/2025#MutualFundMemberhttp://fasb.org/us-gaap-ebp/2025#EmployeeBenefitPlanParticipantDirectedMemberhttp://www.neogen.com/20251231#AllspringSpecialSmallCapValueFundClassR6Memberhttp://fasb.org/us-gaap/2025#MutualFundMemberhttp://fasb.org/us-gaap-ebp/2025#EmployeeBenefitPlanParticipantDirectedMemberhttp://www.neogen.com/20251231#VanguardTargetRetirement2060FundMemberhttp://fasb.org/us-gaap/2025#MutualFundMemberhttp://fasb.org/us-gaap-ebp/2025#EmployeeBenefitPlanParticipantDirectedMemberhttp://www.neogen.com/20251231#VanguardSmallCapGrowthIndexFundAdmiralSharesMemberhttp://fasb.org/us-gaap/2025#MutualFundMemberhttp://fasb.org/us-gaap-ebp/2025#EmployeeBenefitPlanParticipantDirectedMemberhttp://www.neogen.com/20251231#LargeCapGrowthIIIR1Memberhttp://fasb.org/us-gaap/2025#DefinedBenefitPlanCommonCollectiveTrustMemberhttp://fasb.org/us-gaap-ebp/2025#EmployeeBenefitPlanParticipantDirectedMemberhttp://www.neogen.com/20251231#PutnamStableValueFundMemberhttp://fasb.org/us-gaap/2025#DefinedBenefitPlanCommonCollectiveTrustMemberhttp://fasb.org/us-gaap-ebp/2025#EmployeeBenefitPlanParticipantDirectedMemberhttp://www.neogen.com/20251231#RussellMidCapGrowthIIIR1Memberhttp://fasb.org/us-gaap/2025#DefinedBenefitPlanCommonCollectiveTrustMemberhttp://fasb.org/us-gaap-ebp/2025#EmployeeBenefitPlanParticipantDirectedMemberhttp://fasb.org/us-gaap-ebp/2025#EmployeeBenefitPlanEmployerCommonStockFundMemberhttp://fasb.org/us-gaap/2025#CommonStockMemberhttp://fasb.org/us-gaap-ebp/2025#EmployeeBenefitPlanParticipantDirectedMemberDecember 31, 20300000711377neog:EBP001MemberVanguard Target Retirement 2035 Fund2025-12-310000711377neog:EBP001MemberVanguard Target Retirement 2030 Fund2025-12-310000711377Vanguard Target Retirement 2050 Fundneog:EBP001Member2025-01-012025-12-310000711377us-gaap:FairValueInputsLevel3Memberneog:EBP001Memberus-gaap:MutualFundMember2024-12-310000711377neog:EBP001Membersrt:MaximumMember2025-01-012025-12-310000711377neog:EBP001MemberFidelity Small Cap Index Fund2025-12-310000711377neog:EBP001MemberAllspring Special Small Cap Value Fund - Class R62025-12-310000711377neog:EBP001Memberus-gaap:FairValueInputsLevel1Member2024-12-310000711377neog:EBP001MemberLarge Cap Growth III R12025-01-012025-12-310000711377us-gaap:FairValueInputsLevel3Memberneog:EBP001Memberus-gaap:MutualFundMember2025-12-310000711377neog:EBP001Memberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMember2025-12-310000711377neog:EBP001MemberLarge Cap Growth III R12025-12-310000711377neog:EBP001MemberFidelity Mid Cap Index Fund2025-12-310000711377us-gaap:FairValueInputsLevel3Memberneog:EBP001Member2025-12-310000711377Vanguard Equity-Income Fund Admiral Sharesneog:EBP001Member2025-12-310000711377Vanguard Small-Cap Growth Index Fund Admiral Sharesneog:EBP001Member2025-12-310000711377neog:EBP001Memberus-gaap:DefinedBenefitPlanCommonCollectiveTrustMemberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMember2024-12-310000711377neog:EBP001MemberVanguard Explorer Fund Admiral Shares2025-12-310000711377Vanguard Target Retirement 2020 Fundneog:EBP001Member2025-01-012025-12-310000711377neog:EBP001MemberVanguard Target Retirement 2045 Fund2025-12-310000711377neog:EBP001Memberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:DefinedBenefitPlanCommonCollectiveTrustMember2025-12-310000711377neog:EBP001MemberBaird Core Plus Bond Fund Class Institutional2025-12-310000711377neog:EBP001Memberneog:EmployeeBenefitPlansMutualFundsAndCommonStockOfPlanSponsorMember2024-12-310000711377neog:EBP001MemberFidelity Mid Cap Index Fund2025-01-012025-12-310000711377us-gaap:FairValueInputsLevel3Memberneog:EBP001Memberus-gaap-ebp:EmployeeBenefitPlanEmployerCommonStockMember2024-12-3100007113772025-01-012025-12-310000711377neog:EBP001Member2024-12-310000711377neog:EBP001MemberVanguard Target Retirement 2030 Fund2025-01-012025-12-310000711377neog:EBP001Memberus-gaap:MutualFundMember2025-12-310000711377neog:EBP001Membersrt:MinimumMember2025-01-012025-12-310000711377neog:EBP001MemberVanguard Target Retirement 2040 Fund2025-01-012025-12-310000711377neog:EBP001MemberBaird Core Plus Bond Fund Class Institutional2025-01-012025-12-310000711377neog:EBP001Memberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:DefinedBenefitPlanCommonCollectiveTrustMember2025-01-012025-12-310000711377neog:EBP001MemberVanguard Target Retirement 2065 Fund2025-01-012025-12-310000711377neog:EBP001Memberneog:EmployeeBenefitPlansMutualFundsAndCommonStockOfPlanSponsorMember2025-12-310000711377neog:EBP001MemberVanguard Target Retirement 2070 Fund2025-01-012025-12-310000711377Vanguard Target Retirement 2060 Fundneog:EBP001Member2025-12-310000711377us-gaap:FairValueInputsLevel2Memberneog:EBP001Memberus-gaap-ebp:EmployeeBenefitPlanEmployerCommonStockMember2024-12-310000711377us-gaap:FairValueInputsLevel2Memberneog:EBP001Member2025-12-310000711377neog:EBP001Member2025-01-012025-12-310000711377neog:EBP001MemberVanguard Target Retirement 2035 Fund2025-01-012025-12-310000711377neog:EBP001Memberus-gaap:FairValueInputsLevel1Memberneog:EmployeeBenefitPlansMutualFundsAndCommonStockOfPlanSponsorMember2024-12-310000711377neog:EBP001Memberus-gaap:MutualFundMember2024-12-310000711377neog:EBP001MemberVanguard Inflation-Protected Securities Fund Admiral Shares2025-12-310000711377Vanguard Target Retirement 2055 Fundneog:EBP001Member2025-01-012025-12-310000711377neog:EBP001Memberus-gaap-ebp:EmployeeBenefitPlanEmployerCommonStockMember2024-12-310000711377neog:EBP001MemberFidelity U.S. Bond Index Fund2025-12-310000711377us-gaap:FairValueInputsLevel3Memberneog:EBP001Memberneog:EmployeeBenefitPlansMutualFundsAndCommonStockOfPlanSponsorMember2024-12-310000711377neog:EBP001Memberus-gaap-ebp:EmployeeBenefitPlanEmployerCommonStockMember2025-12-310000711377neog:EBP001MemberPutnam Stable Value Fund2025-01-012025-12-310000711377us-gaap-ebp:EmployeeBenefitPlanTrusteeMemberneog:EBP001Memberus-gaap-ebp:EmployeeBenefitPlanEmployerCommonStockMember2024-12-310000711377neog:EBP001MemberFidelity International Index Fund2025-01-012025-12-310000711377neog:EBP001MemberVanguard Explorer Fund Admiral Shares2025-01-012025-12-310000711377neog:EBP001MemberFidelity Government Money Market Fund2025-01-012025-12-310000711377neog:EBP001Memberus-gaap:FairValueInputsLevel1Memberus-gaap:MutualFundMember2025-12-310000711377neog:EBP001Memberus-gaap:DefinedBenefitPlanCommonCollectiveTrustMember2024-12-310000711377neog:EBP001Memberus-gaap:FairValueInputsLevel1Memberus-gaap:MutualFundMember2024-12-310000711377Fidelity Large Cap Growth Index Fundneog:EBP001Member2025-12-310000711377Vanguard Target Retirement 2055 Fundneog:EBP001Member2025-12-310000711377Victory Pioneer Strategic Income Fund Class R6neog:EBP001Member2025-01-012025-12-310000711377JPMorgan Mid Cap Value Fund Class R6neog:EBP001Member2025-12-310000711377American Funds EuroPacific Growth Fund Class R6neog:EBP001Member2025-01-012025-12-310000711377neog:EBP001MemberVanguard Target Retirement 2065 Fund2025-12-310000711377neog:EBP001Memberus-gaap:FairValueInputsLevel1Memberneog:EmployeeBenefitPlansMutualFundsAndCommonStockOfPlanSponsorMember2025-12-310000711377neog:EBP001Memberus-gaap:DefinedBenefitPlanCommonCollectiveTrustMemberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMember2024-01-012024-12-310000711377neog:EBP001MemberVanguard Target Retirement 2070 Fund2025-12-310000711377us-gaap:FairValueInputsLevel3Memberneog:EBP001Memberneog:EmployeeBenefitPlansMutualFundsAndCommonStockOfPlanSponsorMember2025-12-310000711377neog:EBP001MemberVanguard Target Retirement 2040 Fund2025-12-310000711377neog:EBP001MemberVanguard Target Retirement 2060 Fund2025-01-012025-12-310000711377neog:EBP001MemberVanguard Target Retirement Income Fund Investor Shares2025-12-310000711377us-gaap:FairValueInputsLevel3Memberneog:EBP001Member2024-12-310000711377us-gaap:FairValueInputsLevel2Memberneog:EBP001Memberus-gaap:MutualFundMember2024-12-310000711377neog:EBP001MemberFidelity U.S. Bond Index Fund2025-01-012025-12-310000711377Vanguard Target Retirement 2020 Fundneog:EBP001Member2025-12-310000711377neog:EBP001MemberVanguard Inflation-Protected Securities Fund Admiral Shares2025-01-012025-12-310000711377neog:EBP001MemberFidelity 500 Index Fund2025-12-310000711377neog:EBP001MemberRussell Mid Cap Growth III R12025-01-012025-12-310000711377neog:EBP001MemberPutnam Stable Value Fund2025-12-310000711377neog:EBP001MemberFidelity Large Cap Value Index Fund2025-12-310000711377neog:EBP001MemberAllspring Special Small Cap Value Fund - Class R62025-01-012025-12-310000711377neog:EBP001MemberCommon Stock— Neogen Corporation2025-12-310000711377neog:EBP001MemberVanguard Target Retirement 2025 Fund2025-12-310000711377neog:EBP001MemberFidelity Government Money Market Fund2025-12-310000711377us-gaap-ebp:EmployeeBenefitPlanTrusteeMemberneog:EBP001Memberus-gaap-ebp:EmployeeBenefitPlanEmployerCommonStockMember2025-12-310000711377us-gaap:FairValueInputsLevel2Memberneog:EBP001Member2024-12-310000711377neog:EBP001MemberFidelity Large Cap Value Index Fund2025-01-012025-12-310000711377American Funds EuroPacific Growth Fund Class R6neog:EBP001Member2025-12-310000711377neog:EBP001MemberFidelity Small Cap Index Fund2025-01-012025-12-310000711377us-gaap:FairValueInputsLevel2Memberneog:EBP001Memberneog:EmployeeBenefitPlansMutualFundsAndCommonStockOfPlanSponsorMember2025-12-310000711377neog:EBP001Memberus-gaap:FairValueInputsLevel1Memberus-gaap-ebp:EmployeeBenefitPlanEmployerCommonStockMember2024-12-310000711377us-gaap:FairValueInputsLevel2Memberneog:EBP001Memberneog:EmployeeBenefitPlansMutualFundsAndCommonStockOfPlanSponsorMember2024-12-310000711377JPMorgan Mid Cap Value Fund Class R6neog:EBP001Member2025-01-012025-12-310000711377us-gaap:FairValueInputsLevel2Memberneog:EBP001Memberus-gaap:MutualFundMember2025-12-310000711377neog:EBP001Memberus-gaap:DefinedBenefitPlanCommonCollectiveTrustMember2025-12-310000711377neog:EBP001MemberFidelity International Index Fund2025-12-310000711377neog:EBP001MemberCommon Stock— Neogen Corporation2025-01-012025-12-310000711377neog:EBP001Member2025-12-310000711377neog:EBP001MemberFidelity 500 Index Fund2025-01-012025-12-310000711377Vanguard Target Retirement 2050 Fundneog:EBP001Member2025-12-310000711377us-gaap:FairValueInputsLevel2Memberneog:EBP001Memberus-gaap-ebp:EmployeeBenefitPlanEmployerCommonStockMember2025-12-310000711377neog:EBP001Memberus-gaap:FairValueInputsLevel1Memberus-gaap-ebp:EmployeeBenefitPlanEmployerCommonStockMember2025-12-310000711377neog:EBP001MemberRussell Mid Cap Growth III R12025-12-310000711377neog:EBP001MemberAmerican Funds American Balanced Fund Class R62025-12-310000711377Fidelity Large Cap Growth Index Fundneog:EBP001Member2025-01-012025-12-310000711377neog:EBP001MemberVanguard Target Retirement 2045 Fund2025-01-012025-12-310000711377neog:EBP001MemberAmerican Funds American Balanced Fund Class R62025-01-012025-12-310000711377neog:EBP001MemberVanguard Equity-Income Fund Admiral Shares2025-01-012025-12-310000711377Vanguard Small-Cap Growth Index Fund Admiral Sharesneog:EBP001Member2025-01-012025-12-310000711377neog:EBP001Memberus-gaap:FairValueInputsLevel1Member2025-12-310000711377neog:EBP001MemberVanguard Target Retirement Income Fund Investor Shares2025-01-012025-12-310000711377us-gaap:FairValueInputsLevel3Memberneog:EBP001Memberus-gaap-ebp:EmployeeBenefitPlanEmployerCommonStockMember2025-12-310000711377Victory Pioneer Strategic Income Fund Class R6neog:EBP001Member2025-12-310000711377us-gaap-ebp:EmployeeBenefitPlanTrusteeMemberneog:EBP001Member2025-01-012025-12-310000711377neog:EBP001Memberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMember2024-12-310000711377neog:EBP001MemberVanguard Target Retirement 2025 Fund2025-01-012025-12-31iso4217:USDxbrli:sharesxbrli:purexbrli:sharesiso4217:USD

     

    UNITED STATES SECURITIES AND EXCHANGE COMMISSION

    Washington, DC 20549-1004

     

    FORM 11-K

     

     

     

    X ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES

    EXCHANGE ACT OF 1934

     

    For the fiscal year ended December 31, 2025

     

    OR

     

    __ TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES

     

    For the transition period from _____ to _____

     

    Commission file number: 0-17988

     

     

    NEOGEN 401(k) RETIREMENT SAVINGS PLAN

    (Full title of the plan and the address of the plan, if

    different from that of the issuer named below)

     

     

    Neogen Corporation

    620 Lesher Place, Lansing, Michigan 48912

    (Name of issuer of the securities held pursuant to

    the plan and the address of its principal

    executive office)

     

     


     

     

     

     

     

     

     

     

     

     

    Audited Financial Statements

    and

    Supplemental Schedule

     

    Neogen 401(k) Retirement Savings Plan

     

    Years Ended December 31, 2025 and 2024

    with Report of Independent Registered Public Accounting Firm

     

     


     

    Table of Contents

     

     

    Report of Independent Registered Public Accounting Firm

    1

     

     

    Audited Financial Statements

     

     

    Statements of Net Assets Available for Benefits

    3

    Statement of Changes in Net Assets Available for Benefits

    4

    Notes to Financial Statements

    5

     

     

    Supplemental Schedule

     

     

     

     

    Schedule H, Part IV, Line 4i - Schedule of Assets (Held at End of Year)

    13

     

     

    SIGNATURE

    14

     

     

    EXHIBIT INDEX

     

     

     

    Exhibit 23 Consent of Independent Registered Public Accounting Firm

    16

     

     

     

     


     

    REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

     

     

     

    Audit Committee of Neogen Corporation,

    the Plan Administrator, and Plan Participants

    of Neogen 401(k) Retirement Savings Plan

    Lansing, Michigan

    Opinion on the Financial Statements

    We have audited the accompanying statements of net assets available for benefits of the Neogen 401(k) Retirement Savings Plan (the “Plan”) as of December 31, 2025 and 2024, the related statement of changes in net assets available for benefits for the year ended December 31, 2025, and the related notes and schedule (collectively referred to as the “financial statements”).

    In our opinion, the financial statements referred to above present fairly, in all material respects, the net assets available for benefits of the Plan as of December 31, 2025 and 2024, and the changes in net assets available for benefits for the year ended December 31, 2025, in conformity with accounting principles generally accepted in the United States of America.

    Basis for Opinion

    These financial statements are the responsibility of the Plan’s management. Our responsibility is to express an opinion on the Plan’s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (“PCAOB”) and are required to be independent with respect to the Plan in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

    We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud.

    Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits of the financial statements provide a reasonable basis for our opinion.

    1


     

    Supplemental Information

    The accompanying December 31, 2025 supplemental schedule of assets (held at end of year) has been subjected to audit procedures performed in conjunction with our audit of the 2025 Neogen 401(k) Retirement Savings Plan financial statements. The supplemental information is the responsibility of the Plan’s management. Our audit procedures included determining whether the supplemental information reconciles to the financial statements or the underlying accounting and other records, as applicable, and performing procedures to test the completeness and accuracy of the information presented in the supplemental schedules. In forming our opinion on the supplemental information, we evaluated whether the supplemental information, including its form and content, is presented in conformity with the United States Department of Labor’s Rules and Regulations for Reporting and Disclosure under the Employee Retirement Income Security Act of 1974. In our opinion, the supplemental information is fairly stated, in all material respects, in relation to the financial statements as a whole.

     

    /s/ Rehmann Robson LLC

    We have served as Neogen 401(k) Retirement Savings Plan’s independent auditor since 2022.

     

     

    Saginaw, Michigan

    June 25, 2026

     

     

     

     

    2


     

    Neogen 401(k) Retirement Savings Plan

     

    Statements of Net Assets Available for Benefits

    December 31, 2025 and 2024

     

     

    December 31,

     

     

    2025

     

     

    2024

     

    Assets

     

     

     

     

     

    Investments, at fair value:

     

     

     

     

     

    Mutual funds

    $

    102,786,085

     

     

    $

    97,002,628

     

    Common stock of Plan Sponsor

     

    3,224,733

     

     

     

    5,203,906

     

    Collective investment trusts

     

    13,779,113

     

     

     

    4,894,309

     

    Total Investments

     

    119,789,931

     

     

     

    107,100,843

     

     

     

     

     

     

     

    Receivables:

     

     

     

     

     

    Employee contributions

     

    80,944

     

     

     

    53,112

     

    Employer contributions

     

    37,217

     

     

     

    25,432

     

    Notes receivable from participants

     

    969,523

     

     

     

    954,537

     

    Total Receivables

     

    1,087,684

     

     

     

    1,033,081

     

     

     

     

     

     

     

    Total Assets (equal to net assets available for benefits)

    $

    120,877,615

     

     

    $

    108,133,924

     

     

    See accompanying notes to financial statements.

    3


     

    Neogen 401(k) Retirement Savings Plan

     

    Statement of Changes in Net Assets Available for Benefits

    Year Ended December 31, 2025

     

    Additions

     

     

     

    Investment income:

     

     

     

    Net appreciation in fair value of investments

     

    $

    10,848,940

     

    Interest and dividends

     

     

    3,848,764

     

     

     

     

     

    Interest income on notes receivable from participants

     

     

    81,586

     

     

     

     

     

    Contributions:

     

     

     

    Employee contributions

     

     

    8,333,584

     

    Employer contributions

     

     

    3,729,479

     

    Other contributions

     

     

    2,168,054

     

     

     

     

     

    Total contributions

     

     

    14,231,117

     

     

     

     

     

    Total additions

     

     

    29,010,407

     

     

     

     

     

    Deductions

     

     

     

    Benefits paid to participants

     

     

    16,072,674

     

    Administrative expenses

     

     

    194,042

     

     

     

     

     

    Total deductions

     

     

    16,266,716

     

     

     

     

     

    Net change in net assets available for benefits

     

     

    12,743,691

     

     

     

     

     

    Net assets available for benefits at beginning of year

     

     

    108,133,924

     

     

     

     

     

    Net assets available for benefits at end of year

     

    $

    120,877,615

     

     

    See accompanying notes to financial statements.

    4


     

    Neogen 401(k) Retirement Savings Plan

    Notes to Financial Statements

     

    1. Description of the Plan

     

    The following description of the Neogen 401(k) Retirement Savings Plan (Plan) is provided for general information purposes only. Participants should refer to the plan document for more complete information.

     

    General

     

    The Plan is a defined contribution plan covering the employees of Neogen Corporation (the “Plan Sponsor” or “Company”) who meet the age and service requirements. Management of the Company control and manage the operation and administration of the Plan. Fidelity Management Trust Company serves as the trustee of the Plan. Marsh McLennan Agency, LLC serves as the Plan’s investment advisor. The Plan is subject to the provisions of the Employee Retirement Income Security Act of 1974 (ERISA).

     

    Contributions

     

    Each year, participants may contribute a percentage of their pretax annual compensation, as defined in the plan document. Participants may choose to contribute to a Traditional 401(k), Roth 401(k) or both, within the Plan. Participants are eligible for Company matching contributions after attaining six months of service. The Company makes matching contributions as follows: $1.00 for each $1.00 on the first 3% of participant contributions and $0.50 on each $1.00 on the next 2% of participant contributions up to the maximum allowable by the IRS. Contributions are subject to certain Internal Revenue Code (IRC) limitations. Participants may also contribute amounts representing distributions from other qualified defined benefit or defined contribution plans. Effective January 1, 2026, the Company amended the Plan to provide that participants become eligible to receive matching contributions after completing one month of continuous service. In addition, effective April 1, 2026, the Company amended the Plan to permit participants to make after-tax Roth 401(k) contributions, which are in addition to the Plan’s existing Roth 401(k) contribution feature.

    Vesting

     

    Participants are vested immediately in their contributions plus actual earnings thereon. Participants are immediately vested in the Company contribution portion of their account.

    5


     

     

    Forfeitures

     

    Forfeitures of non-vested contributions are used to reduce future employer contributions or pay administrative expenses of the Plan. At December 31, 2025, forfeited non-vested accounts totaled $2,272. At December 31, 2024, forfeited non-vested accounts totaled $129. No forfeited non-vested accounts were utilized in 2025 or 2024.

     

    Participants’ Accounts

     

    Individual accounts are maintained for each Plan participant. Each participant’s account is credited with the participant’s contribution, the Company’s matching contribution, and allocations of Plan earnings, and charged with an allocation of Plan earnings and administrative expenses. Allocations are based on participant earnings or account balances, as defined. The benefit to which a participant is entitled is the benefit that can be provided from the participant’s vested account.

     

    Investments

     

    Participants direct the investment of their contributions into various investment options offered by the Plan. Company contributions are automatically invested and subject to the same allocation percentages as the participant contributions. The Plan currently offers a variety of mutual funds, common stock of the Company, and a selection of collective investment trust options.

     

    Notes Receivable from Participants

     

    Participants may borrow from their fund accounts up to a maximum amount equal to the lesser of $50,000 or 50% of the present value of their account balance. Loan transactions are treated as a transfer to (from) the investment fund from (to) the participant’s loan fund. The loans are secured by the balances in the participants’ accounts and bear interest at a rate commensurate with prevailing interest rates charged by persons in the business of lending money for loans which would be made under similar circumstances. The interest rate on new loans is prime plus one percent at time of origination and shall remain fixed throughout the duration of the loan unless a change is required by applicable law for any participant(s) taking a military leave of absence. Principal and interest are paid ratably through payroll deductions.

     

    Payment of Benefits

     

    Upon termination, a participant may elect to receive either: (a) lump-sum amount equal to the value of the participant’s vested balance in his or her account; or (b) partial withdrawals for those that meet certain Plan provisions.

    6


     

     

    2. Summary of Significant Accounting Policies

     

    Basis of Accounting

     

    The accompanying financial statements are prepared on the accrual basis of accounting in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”).

     

    Investment Valuation and Income Recognition

     

    The Plan’s mutual fund and common stock investments are stated at fair value as of the end of the Plan year based on the quoted market prices of the underlying assets. Purchases and sales of securities are recorded on a trade-date basis. Interest income is recorded on an accrual basis. Dividends are recorded on the ex-dividend date. The net change in fair value of investments includes the Plan's aggregate gains and losses on investments bought and sold as well as held during the year. The Plan’s interests in the collective investment trusts are based on the fair value of each fund’s underlying investments as reported by the fund’s portfolio manager using the audited financial statements of the fund at year-end.

     

    Fair Value Measurements

     

    As defined in the current authoritative guidance, fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The guidance applies to all financial instruments that are measured and reported on a fair value basis. The Plan utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs. Based on the observability of inputs used in the valuation techniques the Plan is required to provide information according to the fair value hierarchy. The fair value hierarchy ranks the quality and reliability of the information used to determine fair values. Financial assets and liabilities carried at fair value will be classified and disclosed in one of the following three categories:

     

    •
    Level 1 – Quoted prices (unadjusted) for identical assets or liabilities in active markets that the entity has the ability to access as of the measurement date.

    •
    Level 2 – Significant other observable inputs other than Level 1 prices such as quoted prices for similar assets and liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data.

     

    •
    Level 3 – Significant unobservable inputs that reflect a company’s own assumptions about the assumptions that market participants would use in pricing an asset or liability.

     

    For the years ended December 31, 2025 and 2024, the application of valuation techniques applied to similar assets and liabilities has been consistent.

     

    7


     

    Notes Receivable from Participants

     

    Notes receivable from participants are measured at their unpaid balance plus any accrued but unpaid interest. Loans in default are reclassified as benefit payments to participants based upon the terms of the Plan document.

     

    Contributions

     

    Contributions from participants are recorded when withheld from compensation. Contributions from the Company are recorded in the period in which they become obligations of the Company.

     

    Expenses

     

    Plan administrative expenses may be paid by either the Plan or the Company, as provided in the Plan document. Expenses that are paid directly by the Company are excluded from these financial statements.

     

    Payments of Benefits

     

    Benefit payments to participants are recorded as deductions from the Plan upon distribution.

     

    Use of Estimates

     

    The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of net assets available for benefits and changes therein. Actual results could differ from those estimates. The Plan utilizes various investment valuation techniques. Investment securities, in general, are exposed to various risks, such as interest rate, credit, and overall market volatility. Due to the level of risk associated with certain investment securities, it is reasonably possible that changes in the values of investment securities will occur in the near term and that such changes could materially affect the amounts reported in the financial statements.

     

    3. Plan Termination

     

    Although it has not expressed any intention to do so, the Company has the right, under the Plan, to discontinue its contributions at any time and to terminate the Plan subject to the provisions set forth in ERISA. In the event the Plan is terminated, participants would become 100% vested in their accounts.

     

    4. Fair Value Measurements

     

    The following is a description of the valuation methodologies used for assets measured at fair value.

     

    Mutual funds:

    Valued at the net asset value of shares held by the Plan at year end. Mutual funds held by the Plan are open-ended mutual funds that are registered with the SEC. These funds are

    8


     

    required to publish their daily net asset value and transact at that price and therefore are deemed to be actively traded.

    Common stock of Plan Sponsor:

    Valued at the year-end closing price reported on the active market on which the security is traded.

    Collective Investment Trusts:

    Valued at net asset value as a practical expedient to estimate fair value at year end.

     

    The preceding methods described may produce a fair value calculation that may not be indicative of net realizable value or reflective of future fair values. Furthermore, although the Plan believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different fair value measurement at the reporting date.

     

    The following tables set forth by level, within the fair value hierarchy, the Plan’s assets at fair value as of December 31, 2025 and 2024.

     

     

     

    Assets at Fair Value as of December 31, 2025

     

     

     

    Level 1

     

     

    Level 2

     

     

    Level 3

     

     

    Total

     

    Assets

     

     

     

     

     

     

     

     

     

     

     

     

    Mutual funds

     

    $

    102,786,085

     

     

    $

    -

     

     

    $

    -

     

     

    $

    102,786,085

     

    Common stock of Plan Sponsor

     

     

    3,224,733

     

     

     

    -

     

     

     

    -

     

     

     

    3,224,733

     

    Total assets in the fair value hierarchy

     

     

    106,010,818

     

     

     

    -

     

     

     

    -

     

     

     

    106,010,818

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Investments measured at net asset value

     

     

    -

     

     

     

    -

     

     

     

    -

     

     

     

    13,779,113

     

    Total investments, at fair value

     

    $

    106,010,818

     

     

    $

    -

     

     

    $

    -

     

     

    $

    119,789,931

     

     

     

     

     

    Assets at Fair Value as of December 31, 2024

     

     

     

    Level 1

     

     

    Level 2

     

     

    Level 3

     

     

    Total

     

    Assets

     

     

     

     

     

     

     

     

     

     

     

     

    Mutual funds

     

    $

    97,002,628

     

     

    $

    -

     

     

    $

    -

     

     

    $

    97,002,628

     

    Common stock of Plan Sponsor

     

     

    5,203,906

     

     

     

    -

     

     

     

    -

     

     

     

    5,203,906

     

    Total assets in the fair value hierarchy

     

     

    102,206,534

     

     

     

    -

     

     

     

    -

     

     

     

    102,206,534

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Investment measured at net asset value

     

     

    -

     

     

     

    -

     

     

     

    -

     

     

     

    4,894,309

     

    Total investments, at fair value

     

    $

    102,206,534

     

     

    $

    -

     

     

    $

    -

     

     

    $

    107,100,843

     

     

    The following tables summarize investments for which fair value is measured using the net asset value per share practical expedient as of December 31, 2025 and 2024. There are no participant redemption restrictions for these investments; the redemption notice period is applicable only to the Plan.

     

    9


     

     

     

     

     

     

     

     

    Redemption

     

     

     

     

     

     

     

     

     

    Frequency (If

     

     

    December 31,

     

     

     

     

    Unfunded

     

    Currently

     

    Redemption

    2025

     

    Fair Value

     

     

    Commitments

     

    Eligible)

     

    Notice Period

    Collective investment trusts

     

    $

    13,779,113

     

     

    n/a

     

    Daily

     

    12 months

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Redemption

     

     

     

     

     

     

     

     

     

    Frequency (If

     

     

    December 31,

     

     

     

     

    Unfunded

     

    Currently

     

    Redemption

    2024

     

    Fair Value

     

     

    Commitments

     

    Eligible)

     

    Notice Period

    Collective investment trusts

     

    $

    4,894,309

     

     

    n/a

     

    Daily

     

    12 months

     

    5. Parties-In-Interest

     

    Certain Plan investments are managed by Fidelity Management Trust Company. Fidelity Management Trust Company is the custodian and trustee of the Plan and, therefore, transactions with Fidelity Management Trust Company qualify as party-in-interest transactions. Fees paid by the Plan for the custodial, advisory, and record keeping services amounted to $194,042 for 2025. Fees paid by the Plan for investment management, auditing and other professional services rendered by parties-in-interest were based on customary and reasonable rates for such services.

     

    The Plan invests in the common stock of Neogen Corporation, the Plan’s Sponsor, a party-in-interest. Investment in Neogen Corporation common stock was $3,224,733 and $5,203,906 as of December 31, 2025 and 2024, respectively. As of December 31, 2025, the investment in Neogen Corporation’s common stock represents 461,335 shares at a market price of $6.99 per share. As of December 31, 2024, the investment in Neogen Corporation’s common stock represents 428,658 shares at a market price of $12.14 per share.

     

    6. Risks and Uncertainties

     

    The Plan invests in common stock of the Plan Sponsor, mutual funds, and common investment trusts with underlying assets consisting of any combination of stocks, bonds, fixed income securities and other investment securities. Investment securities are exposed to various risks, such as interest rate, market, and credit risks. Market risks include global events which could impact the value of investment securities, such as a pandemic or international conflict. Due to the level of interest rate, market, and credit risks inherent with certain of the Plans investment securities, it is at least reasonably possible that changes in the fair values of investment securities will occur in the near term and that such changes could materially affect participants' account balances and the amounts reported in the statements of net assets available for benefits and changes in net assets available for benefits.

     

    10


     

    7. Federal Income Tax Status

     

    The Plan is maintained through the adoption of a pre-approved plan that has received an opinion letter from the IRS dated June 30, 2020, stating that the form of the plan is qualified under Section 401(a) of the Code and therefore, the related trust is tax-exempt. The Plan administrator has determined that it is eligible to, and chose to, rely on the current IRS opinion letter with respect to the qualified status of the Plan. Once qualified, the Plan is required to operate in conformity with the Code to maintain its qualified status. The Plan administrator believes the Plan is being operated in compliance with the applicable requirements of the Code and, therefore, believes the Plan is qualified and the related trust is tax-exempt.

     

    U.S. GAAP requires Plan management to evaluate and recognize a tax liability (or asset) if the Plan has taken an uncertain position that more likely than not would not be sustained upon examination by the IRS. While the Plan may be subject to routine audits of taxing jurisdictions, there are currently no audits for any tax periods in progress.

    

    8. Reconciliation of Financial Statements to Form 5500

     

    The following is a reconciliation of net assets available for benefits per the financial statements to IRS Form 5500 as of December 31, 2025 and 2024:

     

     

    December 31,

     

     

    2025

     

     

    2024

     

    Net assets available for benefits per the financial statements

    $

    120,877,615

     

     

    $

    108,133,924

     

    Deemed distributions reported on 5500

     

    (31,207

    )

     

     

    (47,387

    )

    Net assets available for benefits per the Form 5500

    $

    120,846,408

     

     

    $

    108,086,537

     

     

    Deemed distributions are defaulted and unpaid participant loans of active participants that are reflected as distributions on the Form 5500 and as notes receivable from participants on the financial statements. Upon a distributable event, the deemed distributions will be reflected as distributions in the financial statements.

     

    The following is a reconciliation of changes in net assets available for plan benefits per the financial statements to the Form 5500 for the year ended December 31, 2025:

     

    Increase in net assets available for benefits per the financial statements

    $

    12,743,691

     

    Change in deemed distributions

     

    16,180

     

    Net income per Form 5500

    $

    12,759,871

     

     

    9. Subsequent Events

     

    In preparing the Plan’s financial statements, subsequent events and transactions have been evaluated for potential recognition or disclosure. Plan management determined that there are no subsequent events or transactions that require disclosure to or adjustment in the financial statements through the filing date of this Form 11-K other than the items discussed in Note 1.

     

    11


     

    Supplemental Schedule

    12


     

    Neogen 401(k) Retirement Savings Plan

    Schedule H, Part IV, Line 4i - Schedule of Assets (Held at End of Year)

    As of December 31, 2025

     

     

     

     

     

     

     

     

    (a)

    (b) Identity of Issue, Borrower, Lessor, or Similar Party

     

    (c) Description of investment including maturity date, rate of interest, collateral, par, or maturity value

    (d) Cost

     

    (e) Current Value

     

     

    *

    Fidelity U.S. Bond Index Fund

     

    Mutual Fund

     

    N/A

    $

    1,129,886

     

     

    *

    Fidelity 500 Index Fund

     

    Mutual Fund

     

    N/A

     

    19,509,828

     

     

    *

    Fidelity Mid Cap Index Fund

     

    Mutual Fund

     

    N/A

     

    3,070,235

     

     

    *

    Fidelity Small Cap Index Fund

     

    Mutual Fund

     

    N/A

     

    1,176,420

     

     

    *

    Fidelity International Index Fund

     

    Mutual Fund

     

    N/A

     

    4,200,025

     

     

    *

    Fidelity Large Cap Growth Index Fund

     

    Mutual Fund

     

    N/A

     

    5,073,907

     

     

    *

    Fidelity Large Cap Value Index Fund

     

    Mutual Fund

     

    N/A

     

    758,192

     

     

    *

    Fidelity Government Money Market Fund

     

    Mutual Fund

     

    N/A

     

    14,737

     

     

     

    Vanguard Target Retirement 2055 Fund

     

    Mutual Fund

     

    N/A

     

    7,480,024

     

     

     

    Vanguard Target Retirement 2065 Fund

     

    Mutual Fund

     

    N/A

     

    2,220,763

     

     

     

    JPMorgan Mid Cap Value Fund Class R6

     

    Mutual Fund

     

    N/A

     

    1,135,613

     

     

     

    Vanguard Target Retirement 2020 Fund

     

    Mutual Fund

     

    N/A

     

    219,534

     

     

     

    Vanguard Target Retirement 2030 Fund

     

    Mutual Fund

     

    N/A

     

    3,319,486

     

     

     

    Vanguard Target Retirement 2040 Fund

     

    Mutual Fund

     

    N/A

     

    1,836,702

     

     

     

    Vanguard Target Retirement 2050 Fund

     

    Mutual Fund

     

    N/A

     

    3,291,691

     

     

     

    Baird Core Plus Bond Fund Class Institutional

     

    Mutual Fund

     

    N/A

     

    2,973,304

     

     

     

    Vanguard Target Retirement 2070 Fund

     

    Mutual Fund

     

    N/A

     

    59,815

     

     

     

    Vanguard Equity-Income Fund Admiral Shares

     

    Mutual Fund

     

    N/A

     

    3,752,595

     

     

     

    Vanguard Explorer Fund Admiral Shares

     

    Mutual Fund

     

    N/A

     

    2,562,403

     

     

     

    Vanguard Target Retirement Income Fund Investor Shares

     

    Mutual Fund

     

    N/A

     

    474,703

     

     

     

    Vanguard Target Retirement 2025 Fund

     

    Mutual Fund

     

    N/A

     

    4,654,220

     

     

     

    Vanguard Target Retirement 2035 Fund

     

    Mutual Fund

     

    N/A

     

    9,429,388

     

     

     

    Vanguard Target Retirement 2045 Fund

     

    Mutual Fund

     

    N/A

     

    14,204,394

     

     

     

    Vanguard Inflation-Protected Securities Fund Admiral Shares

     

    Mutual Fund

     

    N/A

     

    578,583

     

     

     

    Victory Pioneer Strategic Income Fund Class R6

     

    Mutual Fund

     

    N/A

     

    778,138

     

     

     

    American Funds EuroPacific Growth Fund Class R6

     

    Mutual Fund

     

    N/A

     

    4,436,202

     

     

     

    American Funds American Balanced Fund Class R6

     

    Mutual Fund

     

    N/A

     

    1,809,937

     

     

     

    Allspring Special Small Cap Value Fund - Class R6

     

    Mutual Fund

     

    N/A

     

    483,697

     

     

     

    Vanguard Target Retirement 2060 Fund

     

    Mutual Fund

     

    N/A

     

    1,977,603

     

     

     

    Vanguard Small-Cap Growth Index Fund Admiral Shares

     

    Mutual Fund

     

    N/A

     

    174,060

     

     

     

    Large Cap Growth III R1

     

    Collective Investment Trust

     

    N/A

     

    7,145,486

     

     

     

    Putnam Stable Value Fund

     

    Collective Investment Trust

     

    N/A

     

    4,522,331

     

     

     

    Russell Mid Cap Growth III R1

     

    Collective Investment Trust

     

    N/A

     

    2,111,296

     

     

     

     

     

     

     

     

     

     

     

     

     

    Common Stock—

     

     

     

     

     

     

     

    *

    Neogen Corporation

    Common Stock

     

    N/A

     

    3,224,733

     

     

     

    Investments at fair value

     

     

     

    $

    119,789,931

     

     

    *

    Notes receivable from participants

    Interest rates of 4.25% to 9.50%, maturing through 2030

     

     

    969,523

     

     

     

    TOTAL

     

     

    $

    120,759,454

     

     

     

    * Party-in-interest

     

     

     

     

     

     

     

     

     

    N/A Not applicable—Cost information is not required with respect to participant or beneficiary directed transactions under an individual account plan.

     

    Employer Identification Number 38-2367843

     

     

     

     

     

     

     

     

     

    Three Digit Plan Number: 001

     

     

     

     

     

     

     

     

     

    13


     

     

    SIGNATURE

    Pursuant to the requirements of the Securities Exchange Act of 1934, the trustees (or other persons who administer the employee benefit plan) have duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

     

     

     

     

     

     

     

     

     

    NEOGEN 401(K) RETIREMENT SAVINGS PLAN

                         (Registrant)

     

     

     

     

    Dated: June 25, 2026

     

    By:

     

    /s/ John Moylan

     

     

     

    John Moylan

     

     

     

    Plan Administrator

     

    14


     

    EXHIBIT INDEX

     

     

    Exhibit No. Description

     

    Exhibit 23 Consent of Independent Registered Public Accounting Firm

     

    15


    Get the next $NEOG alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NEOG

    DatePrice TargetRatingAnalyst
    7/29/2025Outperform → Mkt Perform
    William Blair
    12/19/2024$15.00Buy
    Guggenheim
    6/16/2023$22.00Overweight
    Wells Fargo
    11/22/2022Mkt Perform → Outperform
    William Blair
    7/12/2022$25.00Neutral
    Piper Sandler
    More analyst ratings

    $NEOG
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Neogen® Committed to Helping Ranchers, Livestock Producers, and Horse Owners Fight Against New World Screwworm

    Company expands availability of FIFRA 2(ee) recommendations to counter threat Neogen Corporation (NASDAQ:NEOG), an innovative leader in food and animal safety solutions, today announced the expanded availability of FIFRA* Section 2(ee) recommendations for the use of Prozap® Insectrin X Concentrate and Prozap® Screw Worm and Ear Tick Aerosol as part of New World Screwworm (NWS) response efforts. These recommendations provide ranchers, livestock producers, and horse owners with an additional option to support fly management efforts. In Texas, the Texas Department of Agriculture has approved Section 2(ee) recommendations for these products. Neogen is also making Section 2(ee) recommendatio

    6/18/26 8:45:00 AM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Neogen's Listeria Right Now™ Test Receives AOAC® Performance Tested Methods℠ Certification

    Neogen® Corporation (NASDAQ:NEOG), an innovative leader in food safety solutions, today announced that its Molecular Detection Assay - Listeria Right Now™ rapid environmental monitoring test has received AOAC® Performance Tested Methods℠ (PTM) certification (No. 042604), validating the test's performance for the enrichment-free detection of viable and non-viable Listeria species on stainless steel surfaces. The technology allows technicians to perform the assay without first enriching the sample by growing the bacteria in culture media. Combined with the ease-of-use and speed advantages associated with Neogen's Molecular Detection System ™, this makes Neogen's test one of the fastest molecu

    4/23/26 8:45:00 AM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Neogen Reports Third Quarter Fiscal Year 2026 Financial Results

    Fiscal third quarter 2026 revenue of $211.2 million Food Safety revenue growth of 2.6%, Core Growth1 of 4.0%; Animal Safety revenue growth of (20.1%), Core Growth1 of (8.7%) due primarily to third-party supplier challenges in the quarter Net loss of $17.0 million in the third quarter 2026 with GAAP EPS of $(0.08), Adjusted Net Income of $19.4 million and Adjusted EPS of $0.09 Third quarter 2026 cash flow from operations of $22.7 million and free cash flow of $11.1 million Adjusted EBITDA1 of $48.2 million; Adjusted EBITDA margins1 of 22.8% increases sequentially by 110 basis points Petrifilm® manufacturing transition remains on track for November FY27; Company has initiated

    4/9/26 7:00:00 AM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $NEOG
    SEC Filings

    View All

    SEC Form 11-K filed by Neogen Corporation

    11-K - NEOGEN CORP (0000711377) (Filer)

    6/25/26 5:01:47 PM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form SD filed by Neogen Corporation

    SD - NEOGEN CORP (0000711377) (Filer)

    5/20/26 10:53:38 AM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Neogen Corporation filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - NEOGEN CORP (0000711377) (Filer)

    4/20/26 6:59:24 AM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $NEOG
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO Nassif Mikheal bought $252 worth of shares (23 units at $10.94) (SEC Form 4)

    4 - NEOGEN CORP (0000711377) (Issuer)

    2/17/26 3:12:55 PM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    CEO Nassif Mikheal bought $486 worth of shares (49 units at $9.93) (SEC Form 4)

    4 - NEOGEN CORP (0000711377) (Issuer)

    2/2/26 4:36:07 PM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    CEO Nassif Mikheal bought $1,279 worth of shares (137 units at $9.33) (SEC Form 4)

    4 - NEOGEN CORP (0000711377) (Issuer)

    1/16/26 9:04:01 AM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $NEOG
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Accounting Officer Moylan John Patrick covered exercise/tax liability with 2,553 units of Restricted Stock Units, decreasing direct ownership by 10% to 23,571 units (SEC Form 4)

    4 - NEOGEN CORP (0000711377) (Issuer)

    6/4/26 9:31:58 AM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Former Chief Legal Officer Rocklin Amy M exercised 35,183 shares at a strike of $9.29 and covered exercise/tax liability with 10,241 shares, increasing direct ownership by 44% to 82,182 units (SEC Form 4)

    4 - NEOGEN CORP (0000711377) (Issuer)

    5/19/26 8:37:43 AM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Chief Accounting Officer Moylan John Patrick exercised 4,558 shares at a strike of $9.53 and covered exercise/tax liability with 1,568 shares, increasing direct ownership by 21% to 17,337 units (SEC Form 4)

    4 - NEOGEN CORP (0000711377) (Issuer)

    5/5/26 10:06:57 AM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $NEOG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Neogen downgraded by William Blair

    William Blair downgraded Neogen from Outperform to Mkt Perform

    7/29/25 3:32:27 PM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Guggenheim initiated coverage on Neogen with a new price target

    Guggenheim initiated coverage of Neogen with a rating of Buy and set a new price target of $15.00

    12/19/24 8:18:19 AM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Wells Fargo initiated coverage on Neogen with a new price target

    Wells Fargo initiated coverage of Neogen with a rating of Overweight and set a new price target of $22.00

    6/16/23 7:34:39 AM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $NEOG
    Financials

    Live finance-specific insights

    View All

    Neogen Reports Third Quarter Fiscal Year 2026 Financial Results

    Fiscal third quarter 2026 revenue of $211.2 million Food Safety revenue growth of 2.6%, Core Growth1 of 4.0%; Animal Safety revenue growth of (20.1%), Core Growth1 of (8.7%) due primarily to third-party supplier challenges in the quarter Net loss of $17.0 million in the third quarter 2026 with GAAP EPS of $(0.08), Adjusted Net Income of $19.4 million and Adjusted EPS of $0.09 Third quarter 2026 cash flow from operations of $22.7 million and free cash flow of $11.1 million Adjusted EBITDA1 of $48.2 million; Adjusted EBITDA margins1 of 22.8% increases sequentially by 110 basis points Petrifilm® manufacturing transition remains on track for November FY27; Company has initiated

    4/9/26 7:00:00 AM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Neogen to Release Third-Quarter Fiscal Year 2026 Financial Results on April 9, 2026

    Neogen® Corporation (NASDAQ:NEOG) will issue its third-quarter earnings release before the opening of the market on Thursday, April 9, 2026. Executives from the company will host a webcast and conference call later that morning, beginning at 8:00 a.m. Eastern time. During the call, Neogen management will provide a financial overview and business update of the company's performance for the third-quarter of fiscal year 2026. The conference call can be accessed by dialing: Toll-Free - North America: (1) 888-660-6264 International: (+1) 646-517-3975 Conference ID: 70064# The live webcast can be accessed through Neogen's Investor Relations webpage, neogen.com/investor-relations, under the "E

    3/30/26 8:00:00 AM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Neogen Announces Second-Quarter 2026 Results

    Revenue of $224.7 million, a decrease of 2.8% YoY; Core growth1 increased 2.9% YoY Net loss of $15.9 million; Adjusted Net Income1 of $22.6 million Adjusted EBITDA1 of $48.7 million; Adjusted EBITDA margin1 increased 470 bps sequentially Company hires key senior commercial leaders Petrifilm manufacturing transition remains on track Raising FY 2026 revenue and Adjusted EBITDA guidance 1 Non-GAAP financial measures; see explanations and reconciliations that follow Neogen Corporation (NASDAQ:NEOG) announced today the results of the second quarter ended November 30, 2025. "I am exceptionally proud of the Neogen team as we have initiated the first phase of our strategic tr

    1/8/26 7:00:00 AM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $NEOG
    Leadership Updates

    Live Leadership Updates

    View All

    Neogen® Corporation Announces Appointment of Jennifer Evans Stacey as Chief Legal & Compliance Officer and Board Secretary

    Neogen Corporation (NASDAQ:NEOG), an innovative leader in food safety solutions, today announced the appointment of Jennifer Evans Stacey as Chief Legal & Compliance Officer and Board Secretary. Ms. Stacey is an accomplished chief legal and compliance officer and board secretary with extensive experience in the life sciences industry. She has served more than 10 years as a public company chief legal and compliance officer and board secretary, as well as five years as a public company board member. Over her more than 25-year career, she has led legal, compliance, government relations, corporate communications and human resources functions, operating in complex, fast-moving environments.

    4/8/26 8:00:00 AM ET
    $CNTX
    $NEOG
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: In Vitro & In Vivo Diagnostic Substances

    Neogen® Corporation Announces Appointment of Bryan Riggsbee as Chief Financial Officer

    Neogen® Corporation (NASDAQ:NEOG), a global leader of food safety solutions, is pleased to announce the appointment of Bryan Riggsbee as its new Chief Financial Officer effective November 3, 2025. Riggsbee will oversee Neogen's global finance organization and join the company's Executive Leadership Team, reporting directly to Chief Executive Officer Mike Nassif. To ensure a smooth transition, David Naemura is expected to remain with the Company until the end of the calendar year. Riggsbee brings over 25 years of financial leadership experience across the diagnostics and healthcare industries. He joins Neogen from bioMérieux where he served as Chief Financial Officer of its $2 billion Nort

    10/30/25 8:45:00 AM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Neogen Announces Board Transition with Appointment of Avi Pelossof and the Retirement of William Boehm

    Neogen® Corporation (NASDAQ:NEOG), an innovative leader in food safety solutions, announced today that William Boehm has chosen to retire from the Company's Board of Directors, effective October 23, 2025. Mr. Boehm has served on Neogen's Board since 2011 and currently serves on the Compensation & Talent Management Committee and chairs the Audit Committee. "On behalf of the entire Board and leadership team, I want to express our deep gratitude to Bill for his many years of dedicated service to Neogen," said James C. Borel, Chair of the Neogen Board of Directors. "Bill's insight, guidance, and commitment to our mission have been invaluable in shaping Neogen's path forward. His contributions

    8/14/25 4:15:00 PM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $NEOG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Neogen Corporation

    SC 13G - NEOGEN CORP (0000711377) (Subject)

    11/14/24 4:28:12 PM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form SC 13G filed by Neogen Corporation

    SC 13G - NEOGEN CORP (0000711377) (Subject)

    11/14/24 11:16:20 AM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form SC 13G/A filed by Neogen Corporation (Amendment)

    SC 13G/A - NEOGEN CORP (0000711377) (Subject)

    2/13/24 5:09:41 PM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care